Who is sponsoring PRO-CON?

PRO-CON is sponsored by Jeffrey S Heier.

What condition does PRO-CON study?

PRO-CON studies Age-Related Macular Degeneration.

What drugs are being tested in PRO-CON?

Interventions: Intravitreal aflibercept injection, Placebo.

What is the status of PRO-CON?

PRO-CON is currently COMPLETED.

Last reviewed 2025-10-31 · How we verify

A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) Versus Sham as PROphylaxis Against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes (PRO-CON)

NCT02462889 Phase 2 COMPLETED Results posted

This is a prospective, single-blind, randomized study to evaluate intravitreal aflibercept injection (IAI) versus sham as prophylaxis against conversion to neovascular age-related macular degeneration (AMD) in "high-risk" subjects.

Details

Lead sponsor	Jeffrey S Heier
Phase	Phase 2
Status	COMPLETED
Enrolment	128
Start date	2015-06
Completion	2019-03

Conditions

Age-Related Macular Degeneration

Interventions

Intravitreal aflibercept injection
Placebo

Primary outcomes

Percentage of Subjects Converting to Exudative AMD at 24 Months. — 24 months
Percentage of subjects converting to exudative AMD at 24 months as confirmed by independent masked reading center.

Countries

United States